Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

November 7, 2018

Study Completion Date

March 13, 2019

Conditions

Renal Impairment

Interventions

DRUG

BAY1101042

Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)

Trial Locations (1)

CRS Clinical-Research-Services Kiel GmbH, Kiel